Sumgen Biotech
Hangzhou
About Sumgen Biotech
Jianjian Biotechnology is an antibody drug developer, specializing in the development of therapeutic antibody drugs and the application of antibodies in immunotherapy and immunodiagnosis. Based on CD&MD innovative antibody research and development technology, it has developed products such as tumor immunotherapy antibody drugs and CART antibodies. .
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Total funding: $39.6M
- Funding stage: Late Stage Venture
- Last round: Series C (Dec 2025)
- Website: sumgenbio.com
Industries & Categories
Biotechnology, Clinical Trials, Health Care, Medical
Canonical: https://fsome.com/organization/sumgen-biotech-36476 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.